Literature DB >> 25179250

Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives.

N H Rekers1, E G C Troost2, C M L Zegers2, W T V Germeraad3, L J Dubois2, P Lambin2.   

Abstract

Radiotherapy is along with surgery and chemotherapy one of the prime treatment modalities in cancer. It is applied in the primary, neoadjuvant as well as the adjuvant setting. Radiation techniques have rapidly evolved during the past decade enabling the delivery of high radiation doses, reducing side-effects in tumour-adjacent normal tissues. While increasing local tumour control, current and future efforts ought to deal with microscopic disease at a distance of the primary tumour, ultimately responsible for disease-progression. This review explores the possibility of bimodal treatment combining radiotherapy with immunotherapy.
Copyright © 2014 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Immunothérapie; Radiothérapie stéréotaxique ablative; Stereotactic ablative body radiotherapy

Mesh:

Substances:

Year:  2014        PMID: 25179250     DOI: 10.1016/j.canrad.2014.06.012

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  13 in total

1.  [Stereotactic radiotherapy augments the immune response].

Authors:  Esther G C Troost
Journal:  Strahlenther Onkol       Date:  2016-01       Impact factor: 3.621

2.  Stereotactic Body Radiation Therapy: A useful weapon in anticancer treatment.

Authors:  M Scorsetti
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-23

Review 3.  Radiogenomics and radiotherapy response modeling.

Authors:  Issam El Naqa; Sarah L Kerns; James Coates; Yi Luo; Corey Speers; Catharine M L West; Barry S Rosenstein; Randall K Ten Haken
Journal:  Phys Med Biol       Date:  2017-08-01       Impact factor: 3.609

Review 4.  Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?

Authors:  Olga A Martin; Robin L Anderson; Kailash Narayan; Michael P MacManus
Journal:  Nat Rev Clin Oncol       Date:  2016-08-23       Impact factor: 66.675

5.  The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer.

Authors:  Lei Liu; Li-Min Mu; Yan Yan; Jia-Shuan Wu; Ying-Jie Hu; Ying-Zi Bu; Jing-Ying Zhang; Rui Liu; Xue-Qi Li; Wan-Liang Lu
Journal:  Int J Nanomedicine       Date:  2017-06-01

Review 6.  Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.

Authors:  Reinhard Dummer; Christoph Hoeller; Isabella Pezzani Gruter; Olivier Michielin
Journal:  Cancer Immunol Immunother       Date:  2017-02-25       Impact factor: 6.968

Review 7.  Role of metabolism in cancer cell radioresistance and radiosensitization methods.

Authors:  Le Tang; Fang Wei; Yingfen Wu; Yi He; Lei Shi; Fang Xiong; Zhaojian Gong; Can Guo; Xiayu Li; Hao Deng; Ke Cao; Ming Zhou; Bo Xiang; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  J Exp Clin Cancer Res       Date:  2018-04-23

8.  Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2.

Authors:  Nicolle H Rekers; Catharina Ml Zegers; Wilfred Tv Germeraad; Ludwig Dubois; Philippe Lambin
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

Review 9.  Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.

Authors:  Marvin Kuske; Ricarda Rauschenberg; Marlene Garzarolli; Michelle Meredyth-Stewart; Stefan Beissert; Esther G C Troost; Oliva Isabella Claudia Glitza; Friedegund Meier
Journal:  Am J Clin Dermatol       Date:  2018-08       Impact factor: 7.403

10.  Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells.

Authors:  Hao Chen; Min Luo; Xiangping Wang; Ting Liang; Chaoyuan Huang; Changjie Huang; Lining Wei
Journal:  Cell Mol Biol Lett       Date:  2021-03-16       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.